Pharmaceutical

Rigosertib sodium by Traws Pharma for Epidermolysis Bullosa: Likelihood of Approval

Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Epidermolysis Bullosa.

Apr 19, 2024 - 00:00
Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Epidermolysis Bullosa.
Read the original article

Tags:

Previous Article

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Solid Tumor: Likelihood ...

Next Article

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hodgkin Lymphoma (B-Cell...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

For pharma companies, the possibilities of green chemistry are huge

For pharma companies, the possibilities of green chemis...

Nov 1, 2024

Risk adjusted net present value: What is the current va...

Nov 18, 2023

STAT+: The health care issue Democrats can’t solve: hospital reform

STAT+: The health care issue Democrats can’t solve: hos...

Oct 26, 2023